ESLOF
PINK EssilorLuxottica SA$164.72 ↑ +0.00 (+0.00%) Trading Up from the previous close of $164.72, $3.02 below the day’s high of $167.74
- YTD change
- -48.34%
- vs 20-day SMA
- -4.29%
- vs 200-day SMA
- -29.28%
Price ranges
Price & Performance
-59.15 (-26.42%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 56.2% away from all-time highs of $376.38
- ESLOF is down 48% since the beginning of the year
- ESLOF is down 48% over the past 12 months
- ESLOF is down 10% over the past 1 month
- 0% of all ESLOF investors are betting against ESLOF
ESLOF reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -48.9%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +1.83%
- vs 8-day SMA
- +0.07%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
EssilorLuxottica SA engages in the design, manufacture, and distribution of ophthalmic lenses, frames and sunglasses. It operates through the following segments: Professional Solutions and Direct to Consumer. The Professional Solutions segment represent the wholesale business of the Group, i.e. the supply of the Group's products and services to all the professionals of the eyecare industry (distributors, opticians, independents, third-party e-commerce platforms. The Direct to Consumer segment represents the retail business of the Group, i.e. the supply of the Group products and services directly to the end consumer either through the network of physical stores operated by the Group (brick and mortar) or the online channel (e-commerce). The company was founded by Leonardo Del Vecchio on October 01, 2018 and is headquartered in Charenton-le-Pont, France.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.